Related Experiment Videos
[Miliary pulmonary tuberculosis following intravesical BCG-therapy]
M Youssef1, P Carre, E Asquier
1Service de Pneumologie et d'Explorations Fonctionnelles et Respiratoires, CHU Bretonneau, 2, boulevard Tonnellé, 37044 Tours 1.
Revue De Pneumologie Clinique
|December 31, 2003
Summary
Intravesical BCG immunotherapy can lead to miliary pulmonary tuberculosis in patients. Prompt multi-drug antituberculosis therapy with corticosteroids is crucial for managing this severe BCG complication.
Area of Science:
- Oncology
- Immunology
- Infectious Diseases
Background:
- Intravesical Bacillus Calmette-Guérin (BCG) is a standard immunotherapy for superficial bladder cancer.
- BCG immunotherapy can rarely cause disseminated infections, including tuberculosis.
Observation:
- A patient treated with intravesical BCG for bladder cancer developed symptoms of disseminated infection after the fourth infusion.
- Initial chest X-ray was normal, but subsequent imaging revealed miliary pulmonary tuberculosis.
Findings:
- The patient's condition rapidly deteriorated, necessitating a change from single-drug isoniazid to a three-drug antituberculosis regimen combined with corticosteroids.
- Treatment led to the restoration of the patient's general status and a reduction in pulmonary micronodules over nine months.
Implications:
- This case highlights the potential for severe systemic BCG infections and the importance of early diagnosis and aggressive treatment.
- It underscores the need for careful monitoring of patients undergoing intravesical BCG therapy for bladder cancer.